Opening: Real consultation scenario
▎Consultation scenario “I had two failed IVF attempts in Thailand. The first time, I retrieved 3 eggs, formed 1 blastocyst, and PGT-A detected aneuploidy; the second time, I retrieved 2 eggs and no blastocyst formed. AMH 0.8, I am 43 years old. Is it worth trying again in Kyrgyzstan?” — This is a real question from a patient in a recent consultation.
Module A: Direct answerDirect answer: Can I transfer to Kyrgyzstan after IVF failure in Thailand?
Yes, but three core conditions must be met: available embryos (or sufficient ovarian reserve for another stimulation), a clear cause of failure related to policy restrictions, and physical condition allowing a new cycle. If the cause of failure is embryonic chromosomal abnormalities, and the patient is older with diminished ovarian reserve, Kyrgyzstan’s lenient regulations on PGT policy and egg donation may offer more options. However, it should be noted that the level of assisted reproductive technology, laboratory conditions, and doctor experience in Kyrgyzstan lag behind Thailand, and success rate data is not transparent. A comprehensive failure cause analysis must be completed before referral.
Simply put: Lenient policy ≠ good technology. The referral decision should be based on medical indications, not price or promotion.
Module B: Why this choice existsWhy does this choice exist? — Common causes of IVF failure in Thailand and motivations for referral
Thailand is one of the more mature countries for assisted reproductive technology in Asia, but not all patients succeed. After failure, patients face several choices: change hospitals or doctors in Thailand, return home for treatment, or go to another country. Kyrgyzstan has recently entered the视野 of some patients, mainly due to:
- Policy differences: Thailand has strict restrictions on PGT, gender selection, egg donation, etc., while Kyrgyzstan is relatively lenient.
- Cost considerations: A single cycle in Kyrgyzstan costs about 50,000-80,000 RMB, lower than Thailand’s 80,000-150,000 RMB.
- Geography and visa: Bishkek is relatively close to western China, and the visa process is relatively simple.
- Agency promotion: Some agencies promote Kyrgyzstan as a “low-cost alternative,” but information transparency is low.
But it must be clear: The core reason for failure in Thailand is usually medical (embryo quality, endometrial receptivity, immune factors, etc.), not policy issues. If the cause of failure is technical, transferring to a more technologically advanced center (e.g., USA, Japan, Europe) may be more meaningful than simply pursuing lenient policies.
Module E: Differences between countriesDifferences between countries: Thailand vs. Kyrgyzstan
| Comparison dimension | Thailand | Kyrgyzstan |
|---|---|---|
| Assisted reproductive technology level | High, some centers have international accreditation (JCI), equipped with time-lapse incubators, AI embryo assessment, etc. | Medium, laboratory conditions and equipment vary, very few internationally accredited centers |
| PGT policy | Strictly restricted, only for specific genetic disease indications | Relatively lenient, PGT-A/PGT-M can be performed selectively |
| Egg donation/Gender selection | Many legal restrictions, long waiting times | Lenient policy, wide range of options |
| Single cycle cost (RMB) | 80,000-150,000 | 50,000-80,000 |
| Medical language | English proficiency is high, medical translation is easy to obtain | English proficiency is low, mainly Kyrgyz and Russian, translation quality is uncontrollable |
| Legal protection and dispute resolution | Relatively complete, with medical arbitration mechanisms | Still developing, lack of experience in handling foreign-related medical disputes |
| Success rate (<35 years old) | 50-60% (reported by some centers) | Data not transparent, estimated 30-40% (based on limited data) |
| Cross-border embryo transport | Mature transport channels available (must comply with international liquid nitrogen transport standards) | No mature embryo transport agreement with China, practical operation is difficult |
As seen in the table, Kyrgyzstan’s main advantages are policy flexibility and cost, but it is significantly weaker than Thailand in technical strength and legal protection. For older patients with repeated failure, technical factors are often more critical than policy factors.
Module G: Most easily overlooked detailsMost easily overlooked details
- Cross-border embryo transport is almost impossible: If you have frozen embryos in Thailand, there is currently no mature embryo transport agreement between China and Kyrgyzstan. Cross-border transport of liquid nitrogen tanks involves multiple obstacles such as customs, health quarantine, and laboratory receiving standards in both countries, making practical operation extremely difficult.
- Unstable drug supply chain: Some imported ovulation stimulation drugs (e.g., Gonal-F, Pergoveris) may not be available in Kyrgyzstan, or may need to be purchased from a third country, posing risks of customs seizure and cold chain breakage.
- Accuracy issues with medical translation: English proficiency is low in Kyrgyzstan, and medical translators are often non-medical personnel. Terminology translation errors can lead to dosage deviations and misunderstanding of treatment plans.
- Lack of transparency in laboratory quality control: Most IVF centers in Kyrgyzstan do not disclose key indicators such as laboratory accreditation (e.g., ISO 15189), embryo culture success rate, blastocyst formation rate, making it difficult for patients to assess the true level.
- Post-operative follow-up is difficult to guarantee: Luteal phase support, blood value monitoring, ultrasound follow-up after transfer require continuous medical support, and there are difficulties in coordination for异地 medical care.
Most common pitfalls
- “Guaranteed success” promotional trap: Some agencies exploit patients’ eagerness for success by offering “Kyrgyzstan guaranteed success packages.” There is no guaranteed success in assisted reproduction, especially for older patients with repeated failure. Such promotions are mostly marketing gimmicks.
- Direct referral without failure cause analysis: After failure in Thailand, a complete failure cause investigation (including ERA, EMMA, ALICE, full immune panel, coagulation function, thyroid function, hysteroscopy, etc.) should be completed first. Skipping this step and going directly to Kyrgyzstan is likely to result in repeated failure.
- Underestimating time costs: The entire cycle from initial consultation, stimulation, egg retrieval, culture, PGT to transfer usually takes 4-6 months, and the medical process in Kyrgyzstan may be slower than in Thailand, requiring sufficient time.
- Ignoring visa and residence policies: Medical visas for Kyrgyzstan are usually single-entry with a 30-day stay. For multiple entries or long-term stays, the appropriate visa type must be applied for in advance, otherwise, it may affect the treatment schedule.
- Attracted by low prices while ignoring hidden costs: The 50,000-80,000 RMB is only the basic cost for stimulation + egg retrieval + transfer. PGT testing, embryo freezing, medication, translation, travel, etc., are additional costs, and the total expense may be close to that in Thailand.
Actual process: From failure in Thailand to referral in Kyrgyzstan
- Complete failure cause analysis (1-2 months): Perform hysteroscopy, ERA, full immune panel, chromosome karyotype analysis, PGT-A result review, etc., in Thailand or domestically. Determine whether the cause of failure is embryonic, endometrial, immune, or other factors.
- Screen hospitals in Kyrgyzstan (2-4 weeks): Verify hospital qualifications (whether they hold JCI, ISO certification), doctor backgrounds (whether they have overseas training experience), and laboratory equipment (whether they have time-lapse incubators, AI embryo assessment, PGT platforms) through public channels.
- Initial consultation and treatment plan formulation (1-2 weeks): Submit previous medical records (including stimulation protocols, embryo reports, PGT results, hysteroscopy reports, etc.) via video consultation or in-person visit. The Kyrgyzstan doctor will formulate a new plan based on the situation.
- Ovarian stimulation and egg retrieval (2-3 weeks): Complete stimulation (usually using antagonist protocol or mild stimulation protocol) and egg retrieval surgery in Kyrgyzstan. Confirm the drug supply channel in advance.
- Embryo culture and PGT testing (3-4 weeks): Perform embryo culture, blastocyst biopsy, and PGT testing in the Kyrgyzstan laboratory. Confirm whether the laboratory has a PGT platform and quality control standards.
- Frozen embryo transfer (1-2 months): Perform frozen embryo transfer based on endometrial preparation (natural cycle, hormone replacement cycle). Luteal phase support is needed in Kyrgyzstan or after returning home.
- Post-operative follow-up: Pregnancy test 14 days after transfer. If pregnant, continue luteal phase support until 12 weeks of gestation, with regular monitoring of blood HCG and ultrasound. It is recommended to coordinate follow-up with a domestic reproductive center after returning home.
The entire process usually takes 4-7 months, depending on ovarian response, embryo culture results, PGT cycle, and endometrial preparation.
Module O: Suitable and unsuitable populationsSuitable and unsuitable populations
Suitable for referral to Kyrgyzstan
- The cause of failure in Thailand is clearly policy restrictions (e.g., need for PGT-M, gender selection, egg donation), and the patient is ≤38 years old with acceptable ovarian reserve (AMH ≥1.2, AFC ≥6).
- Limited budget, unable to afford the high costs in Thailand or the USA, and has reasonable expectations for success rate.
- Has reliable channels to obtain real information about the target hospital (e.g., recommendations from friends or relatives who have been treated there, direct contact with the doctor).
Unsuitable for referral to Kyrgyzstan
- Age ≥42 years, low ovarian reserve (AMH <0.5), repeated implantation failure, complex immune factors or endometrial pathology — these patients are better suited for centers with stronger technical capabilities.
- Patients requiring cross-border embryo transport (current channels are not mature).
- Patients who cannot accept language barriers, lack of medical information transparency, and insufficient legal protection.
- Patients who have expectations for “guaranteed success” or “low price” promotions rather than making decisions based on medical indications.
Doctor’s perspective — Referral analysis from a reproductive medicine viewpoint
10-year industry consultant · Observation “After IVF failure in Thailand, I have encountered many patients considering going to Kyrgyzstan. From a medical essence perspective, the core logic of referral should be ‘where can solve the cause of my failure,’ not ‘where is cheap or has lenient policies.’ If the cause of failure is embryonic chromosomal aneuploidy, the solution is to improve egg quality, optimize the stimulation protocol, or use embryo donation, not to do the same thing in another country. If the cause of failure is poor endometrial receptivity, what is needed is ERA and endometrial conditioning, not changing the laboratory. Lenient policies are only meaningful if ‘technology can keep up’ — otherwise, it is a castle in the air.”
From a reproductive medicine perspective, doctors usually recommend: First complete a comprehensive failure cause analysis, then choose the next direction based on the specific cause. Kyrgyzstan can be an option, but it should not be the first choice. For older patients with repeated failure, technical strength, laboratory quality control, and doctor experience are far more important than price and policy.
If you decide to transfer, it is recommended to choose a center that has international accreditation, transparent data disclosure, and dedicated medical translators, and be mentally prepared for the possibility of needing to return to Thailand or domestically for coordination during the process.
Ending: Risk reminder⚠️ Risk reminder Transferring to Kyrgyzstan after IVF failure in Thailand involves multiple risks, including differences in medical technology, language barriers, insufficient legal protection, and unstable drug supply. Before making a decision, please be sure to complete a comprehensive failure cause analysis and verify the true qualifications and data of the target hospital. There are no shortcuts in assisted reproductive treatment; every attempt must be based on thorough medical preparation and rational decision-making. It is not recommended to blindly transfer solely due to price or policy leniency without clarifying the cause of failure.